



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the editor

No obviously adverse pregnancy complications and outcomes of the recovered pregnant women from COVID-19



ARTICLE INFO

Keywords

COVID-19

Pregnant woman

Neonatal outcome

Placental examination

ABSTRACT

The effects of SARS-COV-2 infection on the pregnant women and their fetus growth have attracted worldwide concern. Our case study aimed to investigate the neonatal clinical outcomes of the recovered pregnant women from COVID-19 in China, expecting to provide the clinical references of urgent need for other countries. Our study recruited a total of 12 recovered pregnant women from COVID-19 prior to pregnancy termination. The maternal and neonatal clinical characteristics were recorded. Of them, the placental pathological characteristics of five participants were evaluated following the standard guidelines. Two of them chose induced labour due to being worry about the potential adverse effects of medical treatment for COVID-19 by themselves. For the others, 8 gave birth by cesarean section with certain indications and 2 by vaginal delivery. Their neonates were all live birth with ≥ 37 gestational weeks and high Apgar scores of 9 ~ 10. For the neonate related biological samples, they all have negative results of RNA test, including nasopharyngeal swab, umbilical cord blood, amniotic fluid, vaginal fluid, placenta, or umbilical cord. Most of other pathological indicators of placental examination suggested no abnormal syndromes. Overall, we did not find any abnormal pregnancy complications and neonatal outcomes among them. We concluded that excess adverse effect on the fetus development due to COVID-19 in the recovered pregnant women should be less influential, especially, induce abortion due to the anxiety of COVID-19 treatment should be not advisable.

1. Main Text

The effects of SARS-COV-2 infection on the pregnant women and their fetus growth has attracted worldwide concern [1,2]. It was reported SARS-CoV-2 can localized predominantly at the maternal-fetal interface of the placenta, highlighting its potential reproductive toxicities [3]. Likewise, various medical treatments may cause harmful effects on the fetal development. As of now, previous published studies mainly focused on the clinical characteristics on infected women with Corona Virus Disease 2019 (COVID-19) and their neonates delivered during the infection period [1–6]. These could result in certain anxiety among the infected pregnant women. It was proposed that the psychological stress experienced by pregnant women during the COVID-19 outbreak could contribute to maternal mortality [7]. Thus, our case study aimed to investigate the neonatal clinical outcomes of the recovered pregnant women from COVID-19 in China, expecting to provide the clinical references of urgent need for other countries.

This study was mainly conducted in Renmin Hospital of Wuhan University and the near hospitals in Wuhan City, Hubei Province, China, which was approved by the institutional ethics board (No. WDRY2020-K015). All the pregnant women were diagnosed with COVID-19 referring to the “Diagnosis and Treatment Protocol for COVID-19 (Seventh Trial Edition) issued by the National Health Commission of P. R. China” [8]. The recovered pregnant women from COVID-19 prior to pregnancy termination were recruited, and 12 participants with the sufficient clinical information were finally included. Written informed consent from each participant was obtained. The COVID-19 infection was confirmed based on the laboratory detection of SARS-CoV-2 RNA in

nasopharyngeal swab specimens using quantitative RT-PCR analysis following the instruction of the recommended Kit by Chinese Center for Disease Control and Prevention. Of them, the placental pathological characteristics of five participants were evaluated following the recommended guidelines [9], of which the selected indicators were summarized into four categories, i.e. (1) maternal vascular malperfusion, (2) fetal vascular malperfusion; (3) ascending intrauterine infection, and (4) fibrinoid. The continuous variables were described by mean value \pm standard deviation.

Their demographical and clinical characteristics were provided in Table 1. Overall, their age (years) and body mass index (kg/m^2) were 29.6 ± 3.2 and 23.4 ± 4.6 , respectively. They all had singleton pregnancy and no adverse pregnancy history. Among them, the COVID-19 clinical syndromes were mostly ordinary (75%, 9/12), followed by asymptomatic types (17%, 2/12) and mild type (8%, 1/1). They were infected in three trimesters, i.e. 2 (first trimester), 5 (second trimester), and 5 (third trimester). Their mean duration from infection confirmation to being discharged from hospital were 22 ± 10 days. Prior to pregnancy termination, they were recovered from COVID-19 for 51 ± 34 days ranging from 14 days (#12) to 111 days (#5). For the clinical therapeutics, 9 were treated with antibiotics, 12 with antiviral drugs, 6 with Chinese medicine, 4 with corticosteroid, and 4 with oxygen support. The detailed therapies using antibiotic and antiviral drugs, as well as the Chinese medicine, were provided in Table S1 in the Supplementary Materials. The usage of the antibiotic drugs varied with the individuals, of which Azithromycin was the most frequently used (4/10). For antiviral drugs, most of them used Abidor or Oseltamivir (10/12). Lotus Qingwen Capsules were used among all the five pregnant women who

<https://doi.org/10.1016/j.reprotox.2020.11.008>

Received 22 August 2020

Available online 26 November 2020

0890-6238/© 2020 Elsevier Inc. All rights reserved.

chose the Chinese medicine. Two of them chose induced labour due to being worry about the potential adverse effects of medical treatment for COVID-19 by themselves. For the others, 8 gave birth by cesarean section with certain indications and 2 by vaginal delivery, e.g. cervical scar, fetal macrosomia, gestational diabetes mellitus, preeclampsia, or pregnancy-induced hypertension.

Their neonates were all live birth with ≥ 37 gestational weeks and high Apgar scores of 9–10. For the neonate related biological samples, they all have negative results of RNA test, including nasopharyngeal swab, umbilical cord blood, amniotic fluid, vaginal fluid, placenta, or umbilical cord. For the serum antibody test, all the neonates had IgM negative. Whereas, 6 neonates had IgG positive. Of them, five participants had placental pathological examinations (see Table 2). Overall, some had certain placental infarct, increased syncytial knots, and increased focal perivillous fibrin depositions. Whereas, these symptoms were commonly observed histopathological changes compared to those of normal pregnant women empirically diagnosed by senior pathologists. Most of other pathological indicators suggested no abnormal syndromes. Overall, we did not find any abnormal pregnancy complications and neonatal outcomes among them. Unfortunately, two participants chose induced abortion because of worrying about the

potential effects of medical intervention for COVID-19 treatment using various drugs, though they both did not have any adverse pregnancy complications or corticosteroid therapy.

As of the middle November 2020, more than 1.24 million of people died due to the pneumonia induced by SARS-CoV-2 infection. This sudden pandemic had caused increased strong stress and anxiety levels of pregnant women, which may prevent them from following the appropriate medical advice. From March to May, 16 pregnant women identified as being at high risk have died in Indonesia [7]. This could result in certain social panic among the pregnant women. To treat COVID-19, various drugs were inevitable to be used, including antibiotic therapy, antiviral therapy, and corticosteroid [2]. Their long-term potential effects on the fetal and neonatal developments are still under discussion. Overall, the clinical course and perinatal outcomes of our recruited 12 participants were better than the pregnant women suffering from severe acute respiratory syndrome (SARS) in the first and second trimester pregnancy [10], which is consistent with the weaker lethality of COVID-19 than the SARS for the pregnant women [11]. In our case study, the neonates were all live birth with full term of ≥ 37 gestational weeks. Also, their Apgar scores were in a high range of 9–10, which is comparable to the healthy ones. Thus, our preliminary study suggested

Table 1
Demographical and clinical characteristics of the recovered COVID-19 infected pregnant women.

Characteristics	Participants											
	#1	#2	#3	#4	#5	#6	#7	#8	#9	#10	#11	#12
Age (year)	35	27	30	24	27	31	32	28	30	26	31	33
BMI (kg/m ²)	22.2	22.0	19.4	28.7	21.1	19.3	32.0	31.2	26.6	20.0	19.6	22.6
Gravidity	2	1	1	2	2	3	2	1	1	1	1	2
Parity	1	0	1	1	2	2	1	1	1	1	1	2
History of adverse pregnancy	N	N	N	N	N	N	N	N	N	N	N	N
History of immune disorders	N	N	N	N	N	N	N	N	N	N	N	N
COVID-19 clinical classification	O	A	O	O	O	A	O	O	O	M	O	O
Trimester of infection confirmation	1st	1st	2ed	2ed	2ed	2ed	2ed	3rd	3rd	3rd	3rd	3rd
Gestational age (weeks)												
Infection confirmation	9 ⁺¹	11 ⁺²	17 ⁺¹	17 ⁺³	20 ⁺⁴	26 ⁺⁴	28 ⁺⁰	30 ⁺¹	31 ⁺⁶	32 ⁺¹	35 ⁺⁵	35 ⁺⁵
Recovery	12 ⁺⁶	14 ⁺²	22 ⁺³	19 ⁺²	25 ⁺⁰	29 ⁺³	30 ⁺³	33 ⁺⁰	33 ⁺⁴	37 ⁺⁰	37 ⁺⁰	36 ⁺⁶
Duration (Infection → Recovery)	3 ⁺⁵	3 ⁺⁰	5 ⁺²	1 ⁺⁶	4 ⁺³	2 ⁺⁶	2 ⁺³	2 ⁺⁶	1 ⁺⁵	4 ⁺⁶	1 ⁺²	1 ⁺¹
Pregnancy termination	21 ⁺⁰	17 ⁺¹	37 ⁺⁰	38 ⁺⁶	40 ⁺⁶	39 ⁺⁵	38 ⁺²	39 ⁺⁰	38 ⁺²	39 ⁺¹	41 ⁺⁰	38 ⁺⁵
Duration (Recovery → Pregnancy termination)	8 ⁺¹	2 ⁺⁶	14 ⁺⁴	19 ⁺⁴	15 ⁺⁶	10 ⁺²	7 ⁺⁶	6 ⁺⁰	4 ⁺⁵	2 ⁺¹	4 ⁺⁰	2 ⁺⁰
Complication	N	N	HHR	N	FM	/	PIH	GDM	PID	/	N	GDM
Delivery route	II	II	CS	CS	CS	VD	CS	CS	CS	VD	CS	CS
Indications of delivery	SR	SR	HHR	C-S	FM	/	PIH	GDM	PID	/	BF	SU
Medical treatment												
Antibiotics	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	N	Y
Antiviral drugs	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
Chinese medicine	Y	Y	Y	Y	N	N	N	N	N	Y	Y	N
Corticosteroid	N	N	N	Y	N	N	Y	N	N	Y	Y	N
Non-invasive oxygen support	N	Y	Y	N	N	Y	N	N	N	Y	N	N
Invasive oxygen support	N	N	N	N	N	N	N	N	N	N	N	N
Neonatal sex	/	/	F	F	M	F	M	F	M	M	M	M
Apgar score (1 min, 5 min)	/	/	9,10	9,10	9,10	9,10	9,10	9,9	9,9	9,10	9,10	9,10
Neonatal weight (kg)	/	/	3	3.5	4.2	3.5	3.6	4.5	3.2	2.7	3.5	3
Neonatal asphyxia	/	/	N	N	N	N	N	N	N	Y	N	N
Neonatal death	/	/	N	N	N	N	N	N	N	N	N	N
RNA test?	/	/	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
If Yes, Pos (+) or Neg (-)?	/	/	-	-	-	-	-	-	-	-	-	-
Nasopharyngeal swab	/	/	-	-	-	-	-	-	-	-	-	-
Umbilical cord blood	/	/	-	-	-	-	-	/	/	/	/	/
Amniotic fluid	/	/	-	-	-	-	-	/	/	/	/	/
Vaginal fluid	/	/	-	-	-	-	-	/	/	/	/	/
Placenta	/	/	-	-	-	-	-	/	/	/	/	/
Umbilical cord	/	/	-	-	-	-	-	/	/	/	/	/
Serum antibody test?	/	/	Y	Y	Y	Y	Y	N	Y	Y	Y	N
If Yes, Pos (+) or Neg (-)?	/	/	-	+	+	+	+	/	-	+	+	/
IgG	/	/	-	+	+	+	+	/	-	+	+	/
IgM	/	/	-	-	-	-	-	/	-	-	-	/

“/”, not applicable or data missing; BF: Breech fetus; COVID-19 clinical classification: asymptomatic (A), mild syndrome (M), and ordinary type (O); CS: Caesarean section; C-S: Cervical scar; FM: Fetal macrosomia; GDM: Gestational diabetes mellitus; HHR: High fetal heart rate baseline; II: Induced labour; MP: Mild preeclampsia; PID: Pregnancy in diabetes; PIH: Pregnancy-induced hypertension; SR: Self-request; SU: Scarred uterus; VD: Vaginal delivery.

Table 2

Pathological examination of the placental samples of the selected five pregnant women.

No.	Pathological indicator	#3	#4	#5	#6	#7
Category 1: Maternal vascular malperfusion		0 = No; 1 = Yes				
1.1	Placental infarct (s)	1	1	1	1	0
1.2	Distal villous hypoplasia	0	0	0	0	0
1.3	Accelerated villous maturation pattern	0	0	0	0	0
1.4	Increased syncytial knots	0	1	0	1	1
1.5	Villous agglutination	0	0	0	1	0
Category 2: Fetal vascular malperfusion						
2.1	Avascular fibrotic villi	0	0	0	0	0
2.2	Thrombosis	0	0	0	0	0
2.3	Intramural fibrin deposition	0	0	0	0	0
2.4	Villous stromal-vascular karyorrhexis	0	0	0	0	0
2.5	Stem villous vascular obliteration	0	0	0	0	0
2.6	High-grade fetal vascular malperfusion	0	0	0	0	0
Category 3: Ascending intrauterine infection						
3.1	Maternal inflammatory response (exclude subchorionitis)	0	0	0	0	0
3.2	Fetal inflammatory response	0	0	0	0	0
Category 4: Fibrinoid						
4.1	Increased focal perivillous fibrin depositions	1	1	1	1	1
4.2	Massive perivillous fibrin deposition pattern	0	0	0	0	0
4.3	Maternal floor infarct pattern	0	0	0	0	0
Category 5: Chronic inflammation						
5.1	Chronic intervillitis	0	0	0	0	0
5.2	Chronic plasma cell deciduitis	0	0	0	0	0
5.3	Chronic chorioamnionitis	0	0	0	0	0
Category 6: Evidence of maternal decidual arteriopathy						
6.1	Insufficient vessel remodeling	0	0	0	0	0
6.2	Fibrinoid necrosis	0	0	1	0	0

that there were no significant adverse neonatal outcomes of the recovered pregnant women, if they were treated using appropriate medical care. In China, the guideline to treat the infected pregnant women was regulated in time since February 10th, 2020 by China State Council and updated accordingly [12]. Therefore, the related clinical diagnosis and treatment can be standardized with appropriate therapeutic means. As of now, there were very scarce reports about the death of pregnant women in China.

During the COVID-19 infection period, high ratio of pregnant women chose caesarean section [1,2,6], which is reasonable due to the potential adverse effect of their high body temperature or various drug intake. Similar results were also found in other countries [13]. But, for the recovered ones without severe or critical illness, the excess anxiety about the harmful effect on their fetuses induced by COVID-19 infection should be lowered. This viewpoint was also supported by their placental pathological examination results, which were overall consistent with those from the pregnant women who gave birth during the infection period [4]. In addition, we found that RNA test results for all the neonate-related biological samples were negative. Some of their serum antibody test results were positive, but they did not have IgM positive, which were the critical evidence confirm their infection status. It has been known that IgG has relatively smaller molecular weight than IgM, and may be originated from mothers' body, which has no injuries to the fetus. Our study revealed that placenta seems to protect the fetus from the infection of SARS-CoV-2 with high efficiency after their mothers were cured. Heretofore, the previous reports with large population size did not suggest a significantly increased risk of severe disease among pregnant women [2,6,14]. Our study further indicated that excess adverse effect on the fetus development due to COVID-19 in the recovered pregnant women should be less influential, especially, induced abortion due to the anxiety of COVID-19 treatment should be not advisable. However, it is noted that our clinical case study has very small size of pregnant women and more population should be included in future. Our study results can provide important information of the

previous recovered pregnant women from COVID-19 for reference. This is a unique perspective to initiate more researchers to provide more scientific study design to confirm.

Data description

The data will be available by contacting the corresponding author of this study.

Declaration of Competing Interest

All authors declare they have no actual or potential competing financial interests.

Acknowledgement

This work was conducted by authors' interest. We would like to express our gratitude to the help from Dr. Rongwei Ye (Peking University) and other colleagues from the working group of environmental exposure and human health of the China Cohort Consortium (see the website: <http://chinacohort.bjmu.edu.cn/>).

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.reprotox.2020.11.008>.

References

- [1] R.A.M. Pierce-Williams, J. Burd, L. Felder, R. Khoury, P.S. Bernstein, K. Avila, C. A. Penfield, A.S. Roman, C.A. DeBolt, J.L. Stone, A. Bianco, A.R. Kern-Goldberger, A. Hirshberg, S.K. Srinivas, J.S. Jayakumaran, J.S. Brandt, H. Anastasio, M. Birsner, D.S. O'Brien, H.M. Sedev, C.D. Dolin, W.T. Schettler, A. Suhag, S. Ahluwalia, R. S. Navathe, A. Khalifeh, K. Anderson, V. Berghella, Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study, *Am J Obstet Gynecol MFM* (2020) 100134.
- [2] J. Yan, J. Guo, C. Fan, J. Juan, X. Yu, J. Li, L. Feng, C. Li, H. Chen, Y. Qiao, D. Lei, C. Wang, G. Xiong, F. Xiao, W. He, Q. Pang, X. Hu, S. Wang, D. Chen, Y. Zhang, L. C. Poon, H. Yang, Coronavirus disease 2019 in pregnant women: a report based on 116 cases, *Am. J. Obstet. Gynecol.* 223 (1) (2020) 111 e1–111 e14.
- [3] H. Hosier, S.F. Farhadian, R.A. Morotti, U. Deshmukh, A. Lu-Culligan, K. H. Campbell, Y. Yasumoto, C.B. Vogels, A. Casanovas-Massana, P. Vijayakumar, B. Geng, C.D. Odio, J. Fournier, A.F. Brito, J.R. Fauver, F. Liu, T. Alpert, R. Tal, K. Sziget-Buck, S. Perincheri, C.P. Larsen, A.M. Garipey, G. Aguilar, K. L. Fardelmann, M. Harigopal, H.S. Taylor, C.M. Pettker, A.L. Wyllie, C.S. Dela Cruz, A.M. Ring, N.D. Grubaugh, A.I. Ko, T.L. Horvath, A. Iwasaki, U.M. Reddy, H. S. Lipkind, SARS-CoV-2 infection of the placenta, *J. Clin. Invest.* (2020).
- [4] S. Chen, B. Huang, D.J. Luo, X. Li, F. Yang, Y. Zhao, X. Nie, B.X. Huang, [Pregnancy with new coronavirus infection: clinical characteristics and placental pathological analysis of three cases], *Zhonghua Bing Li Xue Za Zhi* 49 (5) (2020) 418–423.
- [5] Z. Peng, J. Wang, Y. Mo, W. Duan, G. Xiang, M. Yi, L. Bao, Y. Shi, Unlikely SARS-CoV-2 vertical transmission from mother to child: a case report, *J. Infect. Public Health* 13 (5) (2020) 818–820.
- [6] A. Pereira, S. Cruz-Melguizo, M. Adrien, L. Fuentes, E. Marin, T. Perez-Medina, Clinical course of coronavirus disease-2019 in pregnancy, *Acta Obstet. Gynecol. Scand.* 99 (7) (2020) 839–847.
- [7] I. Iftidil, R.P. Fadli, B. Gusmaliza, Y.E. Putri, Mortality and psychological stress in pregnant and postnatal women during COVID-19 outbreak in West Sumatra, Indonesia, *J. Psychosom. Obstet. Gynaecol.* (2020) 1–2.
- [8] National Health Commission of the P. R. China, Diagnosis and Treatment Protocol for 2019-nCoV (Seventh Trial Edition), 2020 (Accessed March 13, 2020; in China), <http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/c3e6945832a438eaae415350a8ce964.pdf>.
- [9] S.J. Benton, A.J. Lafreniere, D. Grynspan, S.A. Bainbridge, A synoptic framework and future directions for placental pathology reporting, *Placenta* 77 (2019) 46–57.
- [10] S.F. Wong, K.M. Chow, T.N. Leung, W.F. Ng, T.K. Ng, C.C. Shek, P.C. Ng, P.W. Lam, L.C. Ho, W.W. To, S.T. Lai, W.W. Yan, P.Y. Tan, Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome, *Am. J. Obstet. Gynecol.* 191 (1) (2004) 292–297.
- [11] V. Smith, D. Seo, R. Warty, O. Payne, M. Salih, K.L. Chin, R. Ofori-Asenso, S. Krishnan, F. da Silva Costa, B. Vollenhoven, E. Wallace, Maternal and neonatal outcomes associated with COVID-19 infection: a systematic review, *PLoS One* 15 (6) (2020) e0234187.
- [12] The State Council of P. R. China, 2020. http://www.gov.cn/xinwen/2020-02/10/content_5476731.htm.
- [13] G. Trippella, M. Ciarcia, M. Ferrari, C. Buzzatti, I. Maccora, C. Azzari, C. Dani, L. Galli, E. Chiappini, COVID-19 in pregnant women and neonates: a systematic

review of the literature with quality assessment of the studies, *Pathogens* 9 (6) (2020).

- [14] L. Chen, Q. Li, D. Zheng, H. Jiang, Y. Wei, L. Zou, L. Feng, G. Xiong, G. Sun, H. Wang, Y. Zhao, J. Qiao, Clinical characteristics of pregnant women with Covid-19 in Wuhan, China, *N. Engl. J. Med.* 382 (25) (2020) e100.

Cuifang Fan

Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan City, 430060, Hubei Province, PR China

Yuping Guo

Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan City, 430060, Hubei Province, PR China

Peng Qu

Jingzhou Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, 430060, Hubei Province, PR China

Suqing Wang*

Department of Preventive Medicine, School of Health Sciences, Wuhan University, Wuhan City, 430060, Hubei Province, PR China

Ming Wang

Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan City, 430060, Hubei Province, PR China

Jingping Yuan

Department of Pathology, Renmin Hospital of Wuhan University, Wuhan City, 430060, Hubei Province, PR China

Chunyan Li

Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan City, 430060, Hubei Province, PR China

Likun Gao

Department of Pathology, Renmin Hospital of Wuhan University, Wuhan City, 430060, Hubei Province, PR China

Yiming Pang^{f,g}

^f Institute of Reproductive and Child Health, Peking University, Key Laboratory of Reproductive Health, National Health Commission of the People's Republic of China, Beijing, 100191, PR China

^g Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, PR China

Zhiwen Li^{f,g}

^f Institute of Reproductive and Child Health, Peking University, Key Laboratory of Reproductive Health, National Health Commission of the People's Republic of China, Beijing, 100191, PR China

^g Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, PR China

Bin Wang^{f,g,**}

^f Institute of Reproductive and Child Health, Peking University, Key Laboratory of Reproductive Health, National Health Commission of the People's Republic of China, Beijing, 100191, PR China

^g Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, PR China

* Corresponding author.

** Corresponding author.

E-mail address: swang2099@whu.edu.cn (S. Wang).

E-mail address: binwangpku@foxmail.com (B. Wang).